$26.81
1.36% yesterday
Nasdaq, Dec 24, 07:00 pm CET

Amphastar Pharmaceuticals Inc Stock price

$26.81
+0.10 0.37% 1M
+2.23 9.07% 6M
-10.32 27.79% YTD
-11.46 29.95% 1Y
-1.86 6.49% 3Y
+7.67 40.07% 5Y
+12.52 87.61% 10Y
+18.06 206.40% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.36 1.36%

New AI Insights on Amphastar Pharmaceuticals Inc Insights AI Insights on Amphastar Pharmaceuticals Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.6b
Net debt
$333.3m
Cash
$276.2m
Shares outstanding
46.4m
Valuation (TTM | estimate)
P/E
11.5 | 7.6
P/S
1.7 | 1.7
EV/Sales
2.2 | 2.1
EV/FCF
14.1
P/B
1.6
Financial Health
Equity Ratio
46.4%
Return on Equity
21.8%
ROCE
10.3%
ROIC
9.2%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$723.3m | $741.9m
EBITDA
$164.0m | $267.1m
EBIT
$149.9m | $231.0m
Net Income
$111.6m | $163.3m
Free Cash Flow
$111.0m
Growth (TTM | estimate)
Revenue
0.0% | 1.4%
EBITDA
-27.4% | 22.6%
EBIT
-30.0% | 12.5%
Net Income
-29.2% | 2.4%
Free Cash Flow
-34.8%
Margin (TTM | estimate)
Gross
49.4%
EBITDA
22.7% | 36.0%
EBIT
20.7%
Net
15.4% | 22.0%
Free Cash Flow
15.4%
More
EPS
$2.3
FCF per Share
$2.4
Short interest
14.8%
Employees
2k
Rev per Employee
$360.0k
Show more

Is Amphastar Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Amphastar Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

Buy
75%
Hold
25%

Financial data from Amphastar Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
723 723
0% 0%
100%
- Direct Costs 366 366
8% 8%
51%
357 357
7% 7%
49%
- Selling and Administrative Expenses 126 126
36% 36%
17%
- Research and Development Expense 67 67
3% 3%
9%
164 164
27% 27%
23%
- Depreciation and Amortization 14 14
19% 19%
2%
EBIT (Operating Income) EBIT 150 150
30% 30%
21%
Net Profit 112 112
29% 29%
15%

In millions USD.

Don't miss a Thing! We will send you all news about Amphastar Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amphastar Pharmaceuticals Inc Stock News

Neutral
The Motley Fool
2 days ago
Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares.
Neutral
Accesswire
10 days ago
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen. The FDA determined that Amphastar's teriparatide is bioequivalent ...
Neutral
Accesswire
about one month ago
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be participating in an Analyst-Moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December 3rd, 2025, at 2:00 pm ET. For access, visit Am...
More Amphastar Pharmaceuticals Inc News

Company Profile

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Head office United States
CEO Yong Zhang
Employees 2,028
Founded 1996
Website amphastar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today